AbbVie, Janssen Win IP Fight Over Cancer Drug Imbruvica

By Britain Eakin (August 19, 2021, 8:07 PM EDT) -- A Delaware federal judge on Thursday ruled in favor of AbbVie and Janssen Biotech Inc. in their 2019 suit against Alvogen over its planned generic version of the blockbuster cancer drug Imbruvica, holding that all four patents in the case were not shown to be invalid.

U.S. Chief District Judge Colm F. Connolly handed down the opinion after a seven-day bench trial in October focused on validity, in which Alvogen Pine Brook LLC USA advanced a slew of invalidity arguments. The decision closes out the primary issues in the suit, which was brought by Johnson & Johnson unit Janssen and the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!